SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000920465-20-000164
Filing Date
2020-12-14
Accepted
2020-12-14 16:21:04
Documents
2
Period of Report
2020-12-10

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_160798084563120.html 4  
1 FORM 4 wf-form4_160798084563120.xml 4 4007
2 POA, ROBERT ROSEN a102408000_1xljpcxpowerofa.htm EX-24 3680
  Complete submission text file 0000920465-20-000164.txt   9099
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Issuer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O HERON THERAPEUTICS, INC 4242 CAMPUS POINT COURT, SUITE 200 SAN DIEGO CA 92121
Business Address
Rosen Robert (Reporting) CIK: 0001555089 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36282 | Film No.: 201386405